Waterbury, CTNCT07646613Now EnrollingIRB Ready

Migraine Clinical Trial in Waterbury, CT

Access cutting-edge migraine treatment through this phase 2 clinical trial at a research site in Waterbury. Study-provided care at no cost to qualified participants.

Sponsored by Aspeya, Inc.

Quick Self-Assessment

See if you qualify for this Waterbury location

Preparing your pre-screening questions…

Expert Care in Waterbury

Access migraine specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related migraine treatment provided free

Apply for This Waterbury Location

Check if you qualify for this migraine clinical trial in Waterbury, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Waterbury

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Waterbury site if eligible
  4. 4Begin participation

About This Migraine Study in Waterbury

This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it. Adults with migraine will receive both the study medication (ASY202) and a placebo (inactive treatment) at different times during the study. Neither participants nor study staff will know which treatment is given at the time. The medication is taken using a handheld dry powder inhaler to treat migraine attacks when they occur. Following screening, eligible participants will be enrolled and randomized to one of two treatments sequences i.e. one treatment sequence will receive ASY202 in treatment period 1 followed by placebo in treatment period 2 and other treatment sequence will receive placebo in treatment period 1 followed by ASY202 in treatment period 2. The study lasts about 16 weeks and includes a screening period, two treatment periods (with a minimum of 7 days washout period between the treatment periods), and a safety follow-up visit.

Sponsor: Aspeya, Inc.

Who Can Participate

Inclusion Criteria

Able to understand study procedures and provide written informed consent
Male or female, 18-65 years of age at Screening
BMI between 18.5-35 kg/m² at Screening
Documented history of migraine (with or without aura) for ≥1 year, consistent with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)
Female participants must be either:
of non-childbearing potential, or
of childbearing potential using protocol required contraception

Exclusion Criteria

Diagnosis of headache conditions other than migraine
History or current diagnosis of coronary artery disease (CAD)
History or current diagnosis of coronary artery vasospasm (including Printz-metal's angina), clinically significant arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation) or peripheral vascular disease, ischemic disease (e.g., Raynaud's syndrome, ischemic bowel syndrome, angina pectoris, myocardial infarction, or documented silent ischemia)
History of percutaneous coronary intervention, cardiac surgery, sepsis or vascular surgery
History or current diagnosis of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, or subarachnoid hemorrhage
Known history or current diagnosis of psychological and/or psychiatric condition that, in the opinion of the Investigator, might interfere with study participation and assessments or participant safety. These conditions may include depression, psychosis, schizophrenia, bipolar disorder, dementia, alcoholism, drug abuse, etc.
Known allergic reactions, hypersensitivity, or contraindications to DHE, other ergot-derived products, or any other excipient in the formulation
Use of strong or moderate CYP3A4 inhibitors within 14 days (or 5 half-lives) or CYP3A4 inducers within 28 days (or 5 half-lives) prior to Randomization
Any clinically significant symptoms or conditions at screening, other than migraine, including but not limited to central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions, or history of such conditions that in the opinion of the Investigator, might interfere with study assessments or participant safety

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Waterbury?

Yes, this clinical trial (NCT07646613) has an active research site in Waterbury, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Migraine Treatment Options in Waterbury, CT

If you're searching for migraine treatment options in Waterbury, CT, this clinical trial (NCT07646613) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Waterbury research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced migraine specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all migraine clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Waterbury, CT

See all heart attack clinical trials recruiting in Waterbury — not just this study.

Browse Heart Attack Trials in Waterbury →

Browse More Trials by Condition

Heart Attack TrialsMigraine TrialsRheumatoid Arthritis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Waterbury?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Waterbury, CT